Inozyme Pharma (INZY)
(Real Time Quote from BATS)
$4.59 USD
-0.01 (-0.22%)
Updated Jul 9, 2024 02:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INZY 4.59 -0.01(-0.22%)
Will INZY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INZY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INZY
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Why Earnings Season Could Be Great for Inozyme (INZY)
INZY: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
Other News for INZY
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
INZY Makes Bullish Cross Above Critical Moving Average
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Inozyme initiated with bullish view at Wells Fargo, here's why